Reveals important new results from clinical trials conducted in Scandinavia, Scotland, Australia, Canada, and the United States. This timely reference reviews the vast body of clinical trial evidence supporting the once controversial view that high levels of serum cholesterol are a major risk factor in coronary heart disease (CHD). The studies presented in Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence promote cholesterol reduction as a highly successful means of preventing heart disease in various populations. Investigates past, current, and upcoming controlled clinical trials of cholesterol-reduction therapies, comparing effects of statins and bile acid sequestrants to triglyceride-lowering drugs and antioxidants. Written by more than 25 distinguished international researchers, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence
highlights historical studies of dietary trials designed to reduce CHD
covers tests of HMG CoA reductase inhibitors for patients with and without CHD
illuminates CHD risk factors such as diabetes, hypertension, obesity, and smoking
explores blood levels of homocysteine and lipoprotein(a) and other recently identified CHD risk factors
reviews metabolism of lipoproteins expressed in high (HDL) and low (LDL) density lipoprotein cholesterol
and more! Containing over 700 instructive tables, drawings, photographs, and bibliographic citations, Cholesterol-Lowering Therapy: Evaluation of Clinical Trial Evidence is a must-read resource for cardiologists, pharmacologists, and upper-level undergraduate, graduate, and medical school students in these disciplines.
Edited by:
Scott M. Grundy
Imprint: CRC Press
Country of Publication: United Kingdom
Dimensions:
Height: 234mm,
Width: 156mm,
Weight: 1.133kg
ISBN: 9780367399320
ISBN 10: 0367399326
Pages: 352
Publication Date: 19 September 2019
Audience:
College/higher education
,
Further / Higher Education
Format: Paperback
Publisher's Status: Active
Cholesterol-Lowering Clinical Trials: A Historical Perspective Scott M. Grundy Scandinavian Simvastatin Survival Study (4S) Terje R. Pedersen The Cholesterol and Recurrent Events Trial (CARE): The Effect of Pravastatin on Coronary Events After Myocardial Infarction in Patients with Average Cholesterol Levels Frank M. Sacks, Marc A. Pfeffer, Lemuel A. Moyé, C. Morton Hawkins, Barry R. Davis, Jean L. Rouleau, Thomas G. Cole, and Eugene Braunwald Lessons from the West of Scotland Coronary Prevention Study (WOSCOPS) James Shepherd and Allan Gaw Program on the Surgical Control of the Hyperlipidemias (POSCH) Trial: A Pivotal 25-Year Study Henry Buchwald The Air Force/Texas Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Primary Prevention of Acute Major Coronary Events in Women and Men with Average Cholesterol Stephen Weis, Michael Clearfield, Lt. Col. John R. Downs, and Antonio M. Gotto, Jr. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study: Clinical Implications for Cardiovascular Practice Andrew M. Tonkin and David Hunt Angiographic Results of Lipid-Lowering Trials: A Systematic Review and Meta-Analysis Cheryl L. Holmes, Michael Schulzer, and G. B. John Mancini Biochemical Correlates of Plaque Progression and Coronary Events Melissa Ferraro-Borgida and David Waters Lipid Therapy to Stabilize the Vulnerable Atherosclerotic Plaque: New Insights into the Prevention of Cardiovascular Events B. Greg Brown and Xue-Qiao Zhao Cholesterol-Lowering Trials with Carotid Ultrasonographic Outcomes Robert P. Byington Cholesterol Lowering Reduces Mortality: The Statins David J. Gordon
